Forteo (teriparatide [rDNA origin]) injection is a new drug that was approved in November 2002 by the US Food and Drug Administration (FDA). Forteo is a recombinant human parathyroid hormone product indicated for the treatment of osteoporosis. In addition to this agent, the FDA recently approved Alinia (nitazoxanide), Abilify (aripiprazole), and Strattera (atomoxetine).
Alinia is used for the treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia in pediatric patients. Abilify is a new psychotropic agent approved for the treatment of schizophrenia. Strattera is a selective norepinehprine reuptake inhibitor indicated for the treatment of attention deficit/hyperactivity disorder (ADHD).
This month's column reviews FDA new product approvals and labeling changes for:
Zoloft (sertraline hydrochloride)
Attention deficit/hyperactivity disorder agents
Nonsteroidal anti-inflammatory agents
Bextra (valdecoxib) tablets
Forteo (teriparatide [rDNA origin]) injection
Medscape Pharmacists. 2002;3(2) © 2002 Medscape
Cite this: December 2002 - Medscape - Dec 30, 2002.